Chinese Company Behind Promising Cell Therapy UX-DA001

A woman with moderate-to-severe Parkinson’s disease has shown striking improvement after receiving an experimental therapy called UX-DA001. Six months following the treatment, her motor symptoms improved almost by half during periods when her usual Parkinson’s drugs weren’t working at their best. She lost an average of 3.6 hours of “OFF” time each day — when her medication wears off — and gained 3.3 extra hours of “ON” time in which she could move without troublesome side-effects. Brain scans offered hard proof: PET imaging revealed that the transplanted cells survived in the right region of her brain and were active, showing signs that they were producing dopamine-transporters as healthy neurons would. There were no serious safety concerns tied to the new cells—side-effects were mild and temporary, including a headache and some involuntary movements after surgery. Beyond better movement, the patient also reported improvements in non-motor symptoms: she slept more soundly, felt less anxious, and saw better control of urinary problems, all contributing to a better quality of life. The therapy works by taking a patient’s own blood cells, reprogramming them into stem cells in the lab, and then turning them into dopamine-producing brain cells. These are implanted into her brain by carefully targeted surgery. Because the cells come from her own body, the risk of rejection is very low, so she didn’t have to take drugs to suppress her immune system. This trial is being run by UniXell Biotechnology, a biotech company based in Shanghai, China, which specialises in cell therapies for neurological diseases. The company was founded in 2021 and operates a large R&D and manufacturing facility. The UX-DA001 therapy has already received regulatory approval to run its Phase 1 clinical trial from both China’s National Medical Products Administration and the U.S. Food and Drug Administration, making it one of the first of its kind to be tested so widely. While the results are exciting, they come from just one patient in an early-stage safety trial. Still, it’s a major step forward: a treatment that doesn’t just manage Parkinson’s symptoms, but may help restore part of the damaged dopamine system using the patient’s own cells.